GlassScriptPhysician profile
Steven J Diamantis
NPI 1972564961
$6,434.67
in general payments reported to CMS, 2019-2025
39 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,795 · 2020: $609 · 2021: $1,014 · 2022: $1,054 · 2023: $897 · 2024: $905 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,043.73 | 2019-2025 | |
| Amgen INC. | $881.87 | 2019-2024 | Repatha, Tavneos |
| Abbott Laboratories | $803.60 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $423.26 | 2019-2024 | Lifevest |
| Pfizer INC. | $387.13 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.51 | 2019-2025 | Jardiance, Ofev |
| E.R. Squibb & Sons, L.L.C. | $292.35 | 2020-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $281.30 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $265.97 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $231.47 | 2021-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Astrazeneca Pharmaceuticals LP | $205.12 | 2019-2024 | Wainua, Breztri, Fasenra |
| Esperion Therapeutics, INC. | $178.04 | 2020-2024 | Nexletol |
| Amarin Pharma, INC. | $177.08 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $147.08 | 2021-2023 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $92.13 | 2021-2025 | Verquvo |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Diamantis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.